RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 985-990

  Liu, Haiyan ^a,b   Xu, Yuanyuan ^a   Chen, Yun ^c   Zhang, Haowen ^a   Fan, Saijun ^a   Feng, Shuang ^a   Liu, Fenju ^a  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Cell growth; Malignant glioma; RNA interference; Secreted protein acidic and rich in cysteine

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; OSTEONECTIN; PROTEIN KINASE B; RAF PROTEIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLONY FORMATION; CONTROLLED STUDY; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 79960309127     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.360     Document Type: Article

References (31)

1. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
2. Bornstein P and Sage EH: Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14: 608-616, 2002.
3. Brekken RA and Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19: 816-827, 2001.
4. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J and Podhajcer OL: The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210-214, 1997.
5. Rumpler G, Becker B, Hafner C, et al: Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol 12: 761-771, 2003.
6. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T and Gutiérrez JA: SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57: 1112-1121, 1998.
7. Golembieski WA, Ge S, Nelson K, Mikkelsen T and Rempel SA: Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 17: 463-472, 1999.
8. Rich JN, Shi Q, Hjelmeland M, et al: Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278: 15951-15957, 2003.
9. Schultz C, Lemke N, Ge S, Golembieski WA and Rempel SA: Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270-6277, 2002.
10. Vajkoczy P, Manger MD, Goldbrunner R, et al: Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int J Cancer 87: 261-268, 2000.
11. Menon PM, Gutierrez JA and Rempel SA: A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: High SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 17: 683-693, 2000.
12. Rich JN, Hans C, Jones B, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: 4051-4051, 2005.
13. McClung HM, Thomas SL, Osenkowski P, et al: SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 419: 172-177, 2007.
14. Golembieski WA, Thomas SL, Schultz CR, et al: HSP27 mediates SPARC-induced changes in glioma morphology, migration and invasion. Glia 56: 1061-1075, 2008.
15. Hannon GJ: RNA interference. Nature 418: 244-246, 2002.
16. Meister G and Tuschl T: Mechanisms of gene silencing by doublestranded RNA. Nature 431: 343-349, 2004.
17. Rempel SA, Golembieski WA, Fisher JL, Maile M and Nakeff A: SPARC modulates cell growth, attachment and migration of U87 Glioma cells on brain extracellular matrix proteins. J Neurooncol 53: 149-160, 2001.
18. Mabuchi S, Ohmichi M, Kimura A, et al: Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500, 2002.
19. Zimmermann S and Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744, 1999.
20. Dumaz N, Hayward R, Martin J, et al: In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491, 2006.
21. Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28: 85-94, 2009.
22. Sathornsumetee S, Hjelmeland AB, Keir ST, et al: AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res 66: 8722-8730, 2006.
23. Funato T, Kozawa K, Fujimaki S and Kaku M: Increased sensitivity to cytosine arabinoside in human leukemia by c-raf-1 antisense oligonucleotides. Anticancer Drugs 12: 325-329, 2001.
24. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
25. Pap M and Cooper GM: Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol Cell Biol 22: 578-586, 2002.
26. Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S and Maggirwar SB: Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol 23: 4649-4662, 2003.
27. Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD and Seldin DC: Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 65: 5792-5801, 2005.
28. Li J, Xing M, Zhu M, et al: Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett 272: 91-101, 2008.
29. Kim L, Liu J and Kimmel AR: The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99: 399-408, 1999.
30. Hanks SK and Hunter T: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576-596, 1995.
31. Li Q and Zhu GD: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2: 939-971, 2002.